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Introduction
Cisplatin, cis-diamminedichloroplatinum(II), is one of the most widely used anticancer drugs. Platinum based chemotherapy cures most cases of advanced testicular cancer and has high efficacy in the treatment of other solid tumors such as ovarian and small-cell lung cancers. The principal cytotoxic mechanism associated with cisplatin is the generation of platinum-DNA adducts, the most significant DNA lesions being 1,2-intrastrand cross links that form across adjacent guanines (Wang and Lippard, 2005) .
Unfortunately, acquired resistance to cisplatin can limit therapeutic potential (Perez, 1998) . There are several resistance mechanisms including decreased intracellular drug accumulation, enhanced cellular detoxification by glutathione and metallothionein, altered DNA repair, and inhibition of apoptosis (Perez, 1998; Huang et al., 2005) . However, these mechanisms do not completely account for the observed in vivo unresponsiveness of certain tumors to cisplatin (Niedner et al., 2001; Schenk et al., 2003) . Accordingly, novel pathways mediating cisplatin resistance exist.
Use of model organisms such as the yeast Saccharomyces cerevisiae, have been instrumental in revealing the molecular basis of cisplatin toxicity. Complex systems driving signal transduction, DNA repair, and the cell cycle -are all highly conserved throughout the eukaryotic lineage. The range of mechanisms that can be probed using S. cerevisiae are those relating to maintenance of viability at the unicellular as opposed to the multicellular level. However, conclusions drawn from studies using these organisms are unambiguous because of the ability to disrupt expression of individual genes. Not surprisingly, these studies confirm the importance of DNA repair pathways including NER, RER, and PR (Grossmann et al., 2001; Beljanski et al., 2004; Wu et al., 2004) . A significant advantage conferred by the use of S.
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Molecular Pharmacology Fast Forward. Published on November 8, 2006 as DOI: 10.1124 at ASPET Journals on June 20, 2017 molpharm.aspetjournals.org Downloaded from cerevisiae genome-wide resources has been the identification of new genes, not associated with DNA repair, that mediate response to cisplatin. For example, elevated levels of phosphodiesterase 2 (Pde2), and the transcription factor Cin5, confer resistance to cisplatin (Burger et al., 2000; Furuchi et al., 2001) . Cells lacking the serine/threonine kinase Sky1, the copper transporter Ctr1 and the nitrogen permease regulator Nrp2, are also resistant to cisplatin (Schenk et al., 2004; Ishida et al., 2002; Schenk et al., 2003) . These strategies, exploiting gene overexpression from genomic libraries or transposon-mediated gene disruption, do not provide comprehensive coverage of the entire genome, since overexpression libraries rarely include all genes, and transposon insertion libraries do not disrupt genes in a random manner. Therefore, we screened the entire set of 4,728 homozygous deletion strains representing deletion of all non-essential open reading frames in S. cerevisiae, to identify genes that lead to sensitivity to cisplatin. A similar screen found 130 deletion strains that were sensitive to cisplatin (Wu et al., 2004) . This screen, however, involved mixing all deletes followed by exposure to cisplatin and extraction of genomic DNA. Molecular barcodes identifying each delete were amplified, and hybridized to an oligonucleotide array, enabling abundance of each deletion strain to be determined (Wu et al., 2004) .
Cisplatin itself is a potent DNA damaging agent. Consequently, a DNA barcode associated with a strain that is sensitive to cisplatin might not be amplified, because it has sustained excessive damage. This would be the case in barcodes bearing consecutive guanines, given the nature of cisplatin-induced DNA damage. Lack of amplification is more likely in strains most sensitive to the drug. To avoid this problem, we individually assessed each delete, as previously described in screens for strains sensitive to the DNA alkylating agent methyl methanesulfonate and TPZ (Tirapazamine), a topoisomerase II inhibitor (Chang et al., 2002; Hellauer et al., This article has not been copyedited and formatted. The final version may differ from this version. (Murakami et al., 2001; Torigoe et al., 2002) . Many genes are upregulated in tumors, though not all of the corresponding proteins play a role in tumor progression.
Our data suggest that correlation between V-ATPase function and cisplatin sensitivity underpins a key relationship between the enzyme and sensitivity to the drug.
Furthermore, we go on to show that reduction in V-ATPase activity increases susceptibility to DNA damage per se, explaining why V-ATPase inhibitors render tumors more sensitive to DNA damaging agents in general.
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Materials and Methods
Yeast Strains and media. The homozygous diploid deletion strains and individual haploid deletion strains were made by the Saccharomyces Gene Deletion Project (Winzeler et al., 1999) . They were obtained from EUROSCARF (Frankfurt, Germany). The parental diploid strain BY4743 was used as control in the screening of the deletion library for sensitivity to cisplatin. BY4742 was used as the control for work using haploid strains. Genes encoding Vma6 or Vma8 sub-units of V-ATPase were deleted in the BY4742 background using a Hygromycin B resistance gene as selectable marker, as described by Goldstein et al. 1999 . Combinations of mutants in the same strain were constructed by standard procedures (Rose et al., 1990) . The genotypes of strains used in this study are listed in Table 1 . Yeast was grown in YPD (1% yeast extract, 2% peptone and 2% dextrose) prepared as described in Rose et al., 1990 . Cisplatin, HU, and MMS were obtained from Sigma (St. Louis, Missouri).
Cisplatin stock solutions were prepared in YPD or phosphate buffered saline (PBS), and stored as aliquots at -20 o C.
Screen for cisplatin-sensitive yeast strains. We determined that the sublethal concentration of cisplatin required to result in visibly slower growth of the parental yeast diploid strain (BY4743) was 250µg/ml. Deletion strains were maintained by growth as arrays of 384 colonies on solid YPD. All replications were automated and were carried out using a 384-pin replicator operated by a Biomek  FX Laboratory Automation Workstation (Beckman Coulter, California). Colonies were picked and resuspended in 50µl YPD in 384 well plates and incubated for 48hrs at 30 0 C (to stationary phase). Each culture (5µl) was transferred to fresh 50µl YPD in 384 well plates and grown to log-phase (14 hours at 30 0 C with intermittent agitation). Replicas of these plates were made on solid YPD media with and without cisplatin (250µg/ml), MOL #30494 8 followed by incubation at 30 0 C. During incubation for 3 days, growth was scored by colony size compared to that of the wild type strain BY4743 (as described in Hellauer et al., 2005) . Mutants showing a significant growth defect or absence of growth after 1 day in the presence of 250ug/ml cisplatin were scored as "x" or "xx". Mutants showing a significant growth defect or absence of growth after 3 days in the presence of 250ug/ml cisplatin were scored as "xxx" or "xxxx".
Assessing sensitivity or viability of individual strains to cisplatin. Cultures were grown in liquid YPD at 30°C to exponential phase and diluted to equal cell density.
Six-fold serial dilutions were spotted across YPD, or YPD containing the concentration of cisplatin indicated in figure legends, followed by incubation at 30°C for 3 days. For viability assays, equal cell densities of exponential phase cultures were incubated in PBS (pH7.4) containing the concentration of cisplatin indicated in figure legends; aliquots were removed after 1 hour, diluted, and spread over YPD plates.
Percentage viability was determined from the number of colonies that appeared after incubation for 3 days at 30°C -as a percentage of the number of colonies that appeared for each strain without cisplatin treatment.
Sensitivity to DNA damaging agents other than cisplatin. Cultures were grown at 30°C to exponential phase and diluted to equal cell density (1 × 10 7 cells/ml (in the presence or absence of 100µg/ml cisplatin) was performed as described by Roberts et al., 2002 . Once stained, cells were visualized within 10 min by confocal laser microscopy using fluorescein filters.
Western blot analysis of Rad53. Exponential phase cultures grown at 30°C were incubated for 1 hour in the presence of cisplatin at concentrations indicated in the figure legends. Yeast protein extracts were prepared from TCA-treated cells and
Rad53 was detected with a rabbit polyclonal antibody (Tercero et al., 2003) . This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Screen for cisplatin-sensitive yeast strain. Hypersensitive strains revealed by screening with a sub-lethal concentration of cisplatin would reveal the identities of genes that normally function in pathways sensitive to this drug. We performed a highthroughput robot-aided screen for sensitivity to 250µg/ml cisplatin, using a collection of 4,728 homozygous diploid yeast deletion mutants, corresponding to non-essential yeast genes. Sensitive mutants were scored by comparison with colony size of the isogenic wild type strain, after incubation for one day. They same colonies were scored again after a further 2 days incubation. Overall, seventy-six strains were sensitive to cisplatin ( Table 2 ). The sensitivity of these mutants was confirmed by individually pinning serial dilutions of deletion strains on 250µg/ml cisplatin and control plates. correlative studies by others (Murakami et al., 2001; Torigoe et al, 2002) . The genes are presented in categories based on known or inferred function (Table 2 ).
Exposure to cisplatin leads to DNA damage, so it was not surprising to find that the largest category, representing 42% of the sensitive strains, was composed of thirty-one strains deleted for genes involved in DNA replication and damage repair.
These mainly fell into the following categories of DNA repair: Nucleotide excision repair -NER (6 genes, including RAD1 and RAD2); Recombination repair of double strand breaks-RER (8 genes, including RAD51 and RAD52); Replication-dependant repair -RR (8 genes, including MUS81 and POL32); Post-replication repair -PR (3 genes, including RAD18). Deletes of two DNA helicases (HPR5 and SGS1) and one topoisomerase (TOP3), were also sensitive. Twenty-three (of the thirty-one strains)
were previously reported to be cisplatin sensitive (Wu et al 2004; Birrell et al., 2002) ;
and seven were reported to be sensitive to TPZ, another anticancer drug that causes DNA damage (Hellauer et al., 2005) . Deletion of genes in the following functional categories also gave rise to cisplatin sensitivity: Cell cycle (10 genes, 
HCM1) and two transporters (TPK1 and GUP1).
The category represented by the second largest number of cisplatin sensitive deletes was composed of strains lacking function of the vacuolar H + translocating
ATPase (V-ATPase). The disruption of V-ATPase function is lethal in all eukaryotic organisms except S. cerevisiae (Graham et al, 2003) . The lethality in higher systems is connected to aspects of V-ATPase function that are more significant in such organisms than they are in a unicellular organism like yeast, such as receptor mediated endocytosis. Yeast has one hormone receptor, the action of which is nonessential, this is in contrast to various essential receptors in membranes of complex organisms (Graham et al, 2003) . This made budding yeast an ideal system to further investigate the role of V-ATPase in cisplatin resistance. We present data to explain This article has not been copyedited and formatted. The final version may differ from this version. V-ATPase mutants are sensitive to cisplatin. The V-ATPase is composed of thirteen subunits (Graham et al., 2003) . Loss of any one of eight V-ATPase subunits led to cisplatin sensitivity ( (Fig. 1A) . In a cell survival assay, rapid loss of viability was exhibited by these mutants in the presence of cisplatin (Fig 1B) .
Vacuolar morphology and acidity are not disrupted by cisplatin. The vacuole of budding yeast is required for protein turnover, nutrient recycling, osmoregulation, storage of amino acids and inorganic phosphate, and maintenance of cytoplasmic pH (Graham et al., 2003) . The vacuole (or an aspect of vacuolar function) may be a target of cisplatin, as loss of V-ATPase function rendered cells hypersensitive to the drug.
To investigate this possibility, we assessed the effect of cisplatin on vacuole morphology and vacuole acidification. Normally, one to five vacuoles can be visualised in wild type cells when stained with a fluorescent dye FM4-64 (Conibear and Stevens, 2002) . Many mutants defective for vacuole function exhibit aberrant morphology of the vacuole itself (Raymond et al., 1992) . Cisplatin at 100µg/ml had no effect on the viability of wild type cells but clearly led to loss of viability in the This article has not been copyedited and formatted. The final version may differ from this version. acidification. The lumen of the vacuole is more acidic than the surrounding cytoplasm, the resulting luminal pH drives numerous vacuole-associated processes (Graham et al., 2003) . Cells were stained with Quinacrine, a fluorescent weak base which is only accumulated in the vacuolar lumen upon acidification (Roberts et al., 2002 (Tercero et al., 2003) . Both vma6∆ and vma8∆ strains are hypersensitive to both agents (Fig 3) . The vacuole itself can act as a detoxification mechanism by accumulation of small molecules via the endocytic machinery. Both vma6∆ and vma8∆ strains, however, are also hypersensitive sensitive to UV irradiation in comparison with the wild type (Fig 3) . Accordingly, it is likely This article has not been copyedited and formatted. The final version may differ from this version. vma6∆rad1∆, vma6∆rev3∆, and vma6∆rad52∆) were more sensitive to cisplatin than the single mutants (Fig 4) . This suggests that involvement of V-ATPase with DNA damage sensitivity is independent of DNA repair pathways. Instead, VATPase mutants could be more sensitive to cisplatin simply because more damage is caused by a given concentration of drug.
Activation of the DNA damage checkpoint in V-ATPase mutants. When yeast cells are treated with cisplatin, the DNA damage checkpoint is activated leading to cell cycle arrest at G2/M. Mutants in components of the checkpoint, display increased sensitivity to cisplatin (Grossmann et al., 1999) . The sensitivity to cisplatin exhibited by strains lacking the S-phase checkpoint protein MRC1, is in agreement with this (Table 2) . Rad53, the effector protein kinase in this pathway, is activated via This article has not been copyedited and formatted. The final version may differ from this version. hyperphosphorylation in response to DNA damage (Tercero et al., 2003) .
Phosphorylated Rad53 is detected as a smear of slowly migrating forms of the protein on western blots immunoprobed with anti-Rad53 antisera. We incubated cells in the presence of various concentrations of cisplatin for 1 hour. The incubation of both wild type and vma6∆ cells with 200µg/ml cisplatin led to the appearance of hyperphosphorylated forms of Rad53, suggesting that lack of V-ATPase activity did not impair the DNA damage checkpoint pathway (Fig. 5) . A single band, which indicated the non-phosphorylated form of Rad53 was detected in the absence of the drug, in both wild type and vma6∆ cells (Fig. 5) . In vma6∆ cells, however, hyperphosphorylated Rad53 was detected on incubation with 50µg/ml cisplatin. In contrast, hyperphosphorylated Rad53 was barely detectable in wild type cells treated in the same way, suggesting that V-ATPase mutants suffered more DNA damage than the wild type cells.
Effect of pH on cisplatin sensitivity. One of the major functions of V-ATPase is maintenance of intracellular pH, by translocating protons from the cytosol into the lumen of the vacuole (Graham et al., 2003) . In both unicellular and multicellular organisms, cytoplasmic pH is reduced when function of the V-ATPase is compromised (Moreno et al., 1998; Murakami et al., 2001 ). The increased DNAdamage sensitivity in the V-ATPase mutants could be due to the acidified cytoplasm.
To investigate the effect of pH on cisplatin sensitivity, we followed viability of cells after incubation with cisplatin in neutral (pH7.4) or acidic (pH5.8) conditions. Wild type yeast cells are efficient at maintaining a constant intracellular pH, even when they are incubated in media buffered to varying pH. This is principally due to the action of a plasma membrane H + translocating ATPase. This enzyme pumps H + out of the cell, consuming upto 40% of total cellular ATP. In order to remove the possibility This article has not been copyedited and formatted. The final version may differ from this version. (Brett et al., 2005) .
Both wild type and vma6∆ cells were more sensitive to cisplatin when incubated at lower pH. The effect of low pH, however, was more dramatic in vma6∆ cells (Fig 6) . In the presence of 20µg/ml cisplatin, the viability of vma6∆ cells at pH5.8 was decreased by ca.76% (by ca.24.% at neutral pH), whereas the viability of the wild type cells at pH5.8 was decreased by ca.25% (by ca.10% at neutral pH). This implies that lower cytoplasmic pH increases sensitivity to DNA damage in V-ATPase mutants.
Discussion
Pathways that modulate cisplatin sensitivity could be induced in tumor cells, and development of agents to inhibit these pathways can overcome the resistance that emerges frequently during treatment. Development of new platinum drugs by substitution of ligands or chloride leaving groups of cisplatin has not been successful in terms of overcoming drug resistance. New approaches can be developed based on discovery of mechanisms the mediate toxicity of this drug.
The budding yeast S. cerevisiae has been used as a powerful tool to identify and investigate pathways targeted by drugs. In the present study, we have applied a systematic approach to search for the nonessential genes in yeast which play a role in the response to cisplatin, leading to the identification of seventy-six deletion strains sensitive to this drug.
Over 40% of the cisplatin sensitive strains lacked various components involved in DNA damage repair. The deleted genes were mainly involved in three DNA repair pathways: replication/postreplication repair (RR and PR, respectively), recombination repair (RER) and nucleotide excision repair (NER). However, none of the components involved in base excision repair (BER) or mismatch repair (MR) were identified in this screen, suggesting that PR, RR and NER are the main mechanisms by which cells repair cisplatin-induced DNA damage, while BER and MR are not involved. This is in agreement with previous studies (Grossmann et al., 2001; Beljanski et al., 2004; Wu et al., 2004) .
A novel insight from our screen is that sister chromatid cohesion plays a role in the response to cisplatin. Dcc1, Ctf8 and Ctf18 are components of a complex required for establishment of sister chromatid cohesion. Cells lacking the genes encoding any of these three proteins are sensitive to cisplatin. Cells lacking another This article has not been copyedited and formatted. The final version may differ from this version. (Strom et al., 2004) . Therefore, it is likely that the Dcc1/Ctf8/Ctf18 complex and Ctf4, facilitate recombination repair (RER) of cisplatin-induced DNA damage. Also, two mutants (asf1∆ and mrc1∆), known to impair the Rad53-dependent DNA damage checkpoint pathway, were sensitive to cisplatin. This is in agreement with work showing that cisplatin causes a checkpoint dependent G2/M arrest (Grossmann et al., 1999) . To support this notion, we showed that cisplatin resulted in hyperphosphorylation of Rad53, indicating the activation of this checkpoint pathway (Fig. 5 ).
Several mutants that compromised cell stress tolerance and signal transduction, were sensitive to cisplatin. In mammalian cells, the oxidative and osmolar stress responses protect cells from cisplatin-induced nephrotoxicity (Hanigan et al., 2005) . Also, genes involved with ribosomal function and protein synthesis were identified as cisplatin-resistant genes. In agreement with this are reports describing cisplatin-induced disruption of the translation initiation complex, and, overexpression of a ribosomal protein conferring resistance to cisplatin (Rosenberg and Sato, 1993; Shen et al., 2006) .
Interestingly, a group of nine genes encoding V-ATPase subunits and an assembly factor for this enzyme, were identified as cisplatin-hypersensitive strains. It is not surprising that so many genes involved in V-ATPase function were identified, given that loss of any V-ATPase sub-unit or assembly factor is known to result in loss of V-ATPase activity (Graham et al., 2003) . In yeast, this enzyme is localized to the membrane of the vacuole, with a smaller population of V-ATPase complexes localized to the endosomal network. In mammalian cells, the enzyme is similarly This article has not been copyedited and formatted. The final version may differ from this version. localized to the lysosome (equivalent to the yeast vacuole) and endocytic compartments. Additionally, the enzyme is localized to the membranes of specialized cells, notably the brush-border membranes of renal proximal tubules (Stevens and Forgac, 1997) . In mammalian cells, one of the V-ATPase subunits is induced by cisplatin (Torigoe et al., 2002) . Furthermore, several genes encoding V-ATPase subunits are up-regulated in drug-resistant tumor cell lines (Martinez-Zaguilan et al., 1999; Murakami et al., 2001) . This increase in levels of V-ATPase in cisplatinresistant cells is correlative, and could be a consequence of drug treatment rather than a cause of resistance. The data we present, however, points towards V-ATPase activity directly contributing to drug tolerance. pathway] double mutants were far more sensitive to cisplatin than the single mutants (Fig 4) . Activation of the DNA damage checkpoint by low concentrations of cisplatin was enhanced in V-ATPase mutants. This suggested that loss of the V-ATPase function facilitates the DNA damage caused by cisplatin.
V-ATPase translocates H
V-ATPase is a regulator of cytoplasmic pH. Consequently, loss of V-ATPase activity leads to intracellular acidification, which may lead to greater levels of cisplatin mediated DNA damage. At lower pH, a greater proportion of hydrolysed cisplatin has an aqua ligand, rather than a hydroxo ligand. This enhances the reactivity of cisplatin as the aquated form is more labile. Chemical activity of cisplatin in vitro is greater at lower pH, promoting DNA platination (Murakami et al., 2001 ). The increased sensitivity to cisplatin in a V-ATPase mutant incubated at lower pH supports this hypothesis. At 50µg/ml cisplatin, it is notable that cell viability of the wild type in pH 5.8 buffer, is similar to cell viability of vma6∆ at pH 7.4. This may well reflect a similar intracellular pH in these cells.
The role played by lower pH, however, must be more complex than straightforward increases in chemical reactivity of drugs, because V-ATPase mutants were also hypersensitive to UV irradiation. Low pH can change DNA conformation (Robinson et al., 1992) . Therefore, sensitivity to DNA damaging drugs or UV irradiation in V-ATPase mutants may be associated with altered DNA conformation at low cytosolic pH, rendering DNA more prone to damage. This may explain why This article has not been copyedited and formatted. The final version may differ from this version. use of V-ATPase inhibitors in human cell lines renders them more sensitive to cisplatin (Laurencot et al., 1995; Murakami et al., 2001; Luciani et al., 2004) .
In mammalian cells, cellular acidosis is an early event in apoptosis. Limiting the drop in cytoplasmic pH represses apoptosis, this being frequently associated with an upregulation of V-ATPase subunits in tumors (Torigoe et al., 2002; Izumi et al., 2003) . Accordingly, enhanced cell death in yeast V-ATPase mutants incubated with cisplatin could be due, in part, to activation of apoptosis caused by lowering of intracellular pH. Some controversy does surround the concept of yeast apoptosis.
However, yeast demonstrates several markers typical of apoptosis including DNA fragmentation, phosphatidylserine externalization, chromatin condensation and histone H2B phosphorylation (Madeo et al., 2004; Ahn et al., 2006) . Furthermore, a growing list of genes that regulate apoptosis in mammalian cells have been identified in yeast, including the Yca1 caspase and the apoptosis inducing factor Aif1 (Madeo et al., 2004) .
We also demonstrated that loss of four genes associated with ribosome function and protein synthesis rendered cells sensitive to cisplatin. Accordingly, we predict that enhancing protein synthesis would confer drug resistance. This is in agreement with recent work involving use of a human epidermoid carcinoma cell line that showed cisplatin resistance is induced by overexpression of the ribosomal protein gene RPL36 (Shen et al., 2006) . Another study revealed that inactivation of the Sky1 kinase in S. cerevisiae led to cisplatin resistance. Monitoring levels of the orthologous protein in testicular tumors revealed that expression of the kinase in cisplatin resistant cells was lower than in tumours from patients who were responding to platinum drug based therapy, so levels of the protein could predict the response to the drug (Schenk et al., 2004) . Such work clearly demonstrates that conclusions drawn from use of the This article has not been copyedited and formatted. The final version may differ from this version. Exponential phase wild type, single and double mutants were diluted to equal cell density and incubated in PBS (pH7.4) containing cisplatin at the concentration indicated; aliquots were removed after 1 hour, diluted, and spread over YPD plates.
Viability was determined from the number of colonies that appeared after incubation at 30°C for 3 days -as a percentage of the number of colonies that appeared for each strain without cisplatin treatment.
This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. Mutants showing a significant growth defect or absence of growth after 1 day in the presence of 250ug/ml cisplatin scored as "×" or "××". Mutants showing a significant growth defect or absence of growth after 3 days in the presence of 250ug/ml cisplatin scored as "×××" or "××××". 
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